PARLIAMENTARY WRITTEN QUESTION
Attention Deficit Hyperactivity Disorder: Drugs (25 July 2024)

The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of this intensive work, some issues have been resolved. Many strengths of lisdexamfetamine and all strengths of atomoxetine capsules and guanfacine prolonged-release tablets are now available. We are working to resolve medicine supply issues, where they remain, for some strengths of lisdexamfetamine and methylphenidate. These are anticipated to resolve by August and October 2024, respectively.

We are asking suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term.

The Department has worked with specialist clinicians to develop management advice for National Health Service clinicians, to consider prescribing available alternative brands of methylphenidate prolonged release tablets. We would expect ADHD service providers and specialists to follow our guidance to offer rapid response to primary care teams seeking urgent advice for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.

To aid ADHD service providers and prescribers further, we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients. Further information is available at the following link:

https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/